Neu dierentiation factor (NDF)/heregulin activates ErbB2 via heterodimerization with the NDF receptors ErbB3 and ErbB4. Cells which express normal levels of these receptors are often growth stimulated by NDF, whereas SKBR3, and other ErbB2-overexpressing breast tumour cells are growth inhibited. We demonstrate here that in SKBR3 cells, NDF induces G1 progression but also causes a G2 delay from day 1 and apoptosis from days 2 ± 3. G1 progression was associated with ErbB2 transactivation of ErbB3 and subsequent stimulation of the phosphatidylinositol 3-kinase (PI3K) pathway whereas apoptosis was dependent on p38 MAPK. Inhibition of ERK1/ERK2 had no eect on cell cycle progression or apoptosis. Activation of ErbB3 and PI3K was also seen with betacellulin (BTC) but not epidermal growth factor (EGF) and correlated with the growth eects of these ligands. All three ligands induced shortterm activation of p38 MAPK in a c-Src-dependent manner. However, only NDF caused a second, c-Srcindependent increase in p38 MAPK activity which was required for apoptosis.
Introduction
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (ErbB1/EGFR), ErbB2 (neu, HER2), ErbB3 and ErbB4. The four receptors are widely expressed in epithelial, mesenchymal and neuronal tissues and play fundamental roles during development. Ampli®cation and/or overexpression of erbB-2 is observed in tumours arising at many sites, including breast and ovary (Berger et al., 1988; Slamon et al., 1989) where it correlates with an unfavourable patient prognosis (Hynes and Stern, 1994) .
The epidermal growth factor (EGF)-related peptides, which serve as ligands for ErbB receptors (Salomon et al., 1995; Burden and Yarden, 1997; Riese and Stern, 1998) , fall into three groups: those like EGF which bind ErbB1; those like betacellulin (BTC) which bind ErbB1 and ErbB4; and Neu dierentiation factors (NDFs) or heregulins which bind ErbB3 and ErbB4. Ligand binding to the extracellular domain promotes ErbB receptor homo-and heterodimerization.
Although no direct ligand for ErbB2 has been identi®ed, it appears to be the preferred heterodimerization partner of all ErbB receptors (Karunagaran et al., 1996; Graus-Porta et al., 1997) . Upon ligandinduced ErbB receptor dimerization, the receptors autophosphorylate on speci®c tyrosine residues in their cytoplasmic domains. These serve as docking sites for phosphotyrosine binding intracellular signalling proteins.
NDF stimulates the in vivo growth of mammary epithelium (Jones et al., 1996) and the in vitro growth of normal mammary cells and breast tumour cell lines with low levels of ErbB2 (Marte et al., 1995; GrausPorta et al., 1995; Beerli and Hynes, 1996; Lewis et al., 1996) . However, we have recently shown that NDF treatment of ErbB2 overexpressing breast tumour cells has a growth inhibitory eect. In one such cell line, SKBR3, NDF induces apoptosis from G2/M . The dierent cellular responses to NDF are very likely dependent upon the array of ErbB receptors activated and the intracellular signalling pathways engaged. The four ErbB receptors show a great deal of overlap in the signalling molecules to which they couple. However, there are some examples of more speci®c ErbB binding substrates (Fazioli et al., 1993; Levkowitz et al., 1996; Zrihan-Licht et al., 1997; Riese and Stern, 1998) . The aim of this study was to identify the pathways involved in NDF-induced growth and apoptosis. A comparison of the eects of three ErbB ligands, EGF, BTC and NDF, which promote dierent biological responses in SKBR3 cells, enabled us to identify the receptors and pathways involved in these responses. Furthermore, the use of speci®c kinase inhibitors allowed us to distinguish between a pathway inducing cell cycle progression and one inducing apoptosis. The results suggest that NDF-induced activation of the ErbB2/ErbB3 heterodimer and coupling to the PI3K pathway promotes cell cycle progression. NDF-induced apoptosis was dependent upon activation of p38 MAPK, a stress activated kinase which has been associated with apoptosis (Xia et al., 1995; Schwenger et al., 1997) .
Results

NDF induces G1 progression but a delay in G2
Treatment of SKBR3 breast tumour cells with dierent ErbB ligands has diverse eects on their growth; EGF has no eect, BTC stimulates growth, and NDF inhibits growth and induces apoptosis . NDF-induced apoptosis is preceded by an accumulation of cells in G2/M suggestive of a cell cycle block. However, a shorter G1 phase would also increase the relative number of cells in G2/M and would be consistent with the growth stimulating eect of NDF in other cell lines (Marte et al., 1995; Beerli and Hynes, 1996; Jones et al., 1996) . To address this further, control or NDF-treated cells were labelled with bromodeoxyuridine (BrdU) for 3 h during the ®rst or second day of NDF treatment. Staining and FACS analysis of cells immediately after BrdU labelling revealed increased S phase (BrdU labelled) fraction in NDF treated cells suggesting a shorter G1 (Table 1) . FACS analysis of BTC-treated SKBR3 cells also suggested a shorter G1 phase whereas EGF had no eect on the cell cycle pro®le (data not shown). This is consistent with the growth eects of these ligands.
Cells were also harvested 9 h after removal of BrdU in order to follow their progression beyond S phase. Table I shows that in NDF-treated cultures, fewer labelled cells had progressed through G2/M. To con®rm that NDF induces a G2/M delay, we synchronized SKBR3 cells in G1/S using hydroxyurea and followed their progression through the cell cycle upon release into normal medium or medium containing NDF. Figure 1a shows that control and NDFtreated cells entered G2/M at a similar time (4 ± 10 h). However, compared to untreated controls, NDFtreated cells were delayed in G2/M. The G2/M delay was ®rst evident at 14 h, well before the ®rst signs of apoptosis at 2 days . In a separate experiment, we observed that BTC also caused a G2/M delay whereas EGF had essentially no eect on the cell cycle. (Percentage G2/M at 20 h after release; control=21.1; NDF=26.6; BTC=24.9; EGF=22.0). Taken together, these data suggest that NDF and BTC induce progression from G1 into S but cause a delay in G2/M, with NDF having the strongest eect.
To determine whether the NDF-induced cell cycle delay occurs at G2 or M phase, we examined the levels of cyclins A and B and the Tyr15 phosphorylation status of Cdk1 (cdc2) by Western blot analysis of SKBR3 lysates. Figure 1b shows that levels of cyclin A and cyclin B are increased following 1 day and 3 day NDF treatment which is consistent with an increased G2/M fraction. After 1 day and 3 days of NDF treatment, Tyr15 phosphorylation on Cdk1 is higher than in controls. This is indicative of cells accumulating in a premitotic phase since Cdc25C mediated dephosphorylation of Tyr15 is necessary for Cdk1 activation and entry into M phase (Millar et al., 1991) .
NDF, BTC and EGF induce dierential activation of ErbB3
SKBR3 cells have moderate levels of ErbB1 and ErbB3 and overexpress ErbB2. In SKBR3 cells, NDF induces heterodimers of ErbB2 with ErbB3, whereas BTC and EGF activate heterodimers of ErbB2 with ErbB1. EGF and BTC can, to dierent extents, activate ErbB3 via lateral transmission of the signal (Beerli and Graus-Porta et al., 1997) . We examined ErbB receptor activation following treatment of SKBR3 cells with these ligands in an attempt to identify the receptor(s) linked to G1 progression (NDF and BTC but not EGF) and/or apoptosis (NDF but not BTC or EGF). ErbB2 has a high basal level of tyrosine phosphorylation in SKBR3 cells, presumably due to dimeriza- Low density cultures of SKBR3 cells were incubated in normal medium plus or minus 1 nM NDF for 12 h (day 1) or 36 h (day 2). BrdU was added at 10 mM for 3 h and then the cells were either harvested by trypsinization immediately (percentage S phase) or washed and incubated in normal medium for another 9 h prior to harvesting (percentage progressed to next G1). Cells were stained with FITC conjugated anti-BrdU antibody and propidium iodide (PI) as described in Materials and methods and analysed by FACS analysis. Percentage S phase=percentage BrdU positive cells and percentage progressed to next G1=percentage of labelled cells in G1 at 9 h after BrdU labelling and levels of cyclin A and B. SKBR3 cells were left untreated (con) or treated with 1 nM NDF for 1 or 3 days. 50 mg total protein was subjected to SDS ± PAGE (12% gel), blotted and probed for the indicated proteins using the antisera described in the Materials and methods tion induced by overexpression. NDF treatment had little eect on the total phosphotyrosine content of ErbB2. However, qualitative dierences in tyrosine phosphorylation were not ruled out and a mobility shift suggested serine/threonine phosphorylation . To examine this further, we performed two-dimensional tryptic phosphopeptide mapping on ErbB2 from non-stimulated and NDF, EGF and BTC treated SKBR3 cells. The maps generated by ErbB2 are quite complex. However, the pattern of speci®c tryptic phosphopeptides is qualitatively similar to our previous published maps, obtained with ErbB2 from cells expressing lower levels of the protein (Olayioye et al., 1998) . To assist comparison we have used the same lettering system in the current study (Figure 2 ). Peptides a 1 -a 3 were previously found in basally phosphorylated ErbB2 (Olayioye et al., 1998) . In untreated SKBR3 cells, in addition to a 1 -a 3 , peptides b, c, e, f and g, which were previously seen only in ligand stimulated cells (Olayioye et al., 1998) , are also present. Peptides i and j are novel. Due to the high basal level of ErbB2 tyrosine phosphorylation in SKBR3 cells, it is not surprising to detect peptides which were previously observed only upon ligand activation (Olayioye et al., 1998) . Ligand treatment of SKBR3 cells led to the appearance of two major phosphopeptides,`d' which we previously observed (Olayioye et al., 1998) , and`k' which is novel. Furthermore, especially three of the basal phosphopeptides showed increased intensity after ligand treatment (g, f and j). The ligand induced peptides are labelled in Figure 2 (EGF). Despite the dierent biological responses to the three ligands, no dierences were seen between ErbB2 activated via EGF, NDF or BTC treatment suggesting that the dimerization partner may play a more important role than ErbB2 in promoting the dierential eects of these ligands. In order to address this possibility, ErbB3 activation was examined in control and ligand treated SKBR3 cells. Figure 3 shows that ErbB3 is phosphorylated on tyrosine even in unstimulated cells. Both NDF and BTC increased tyrosine phosphorylation of ErbB3, whereas EGF did not (Figure 3) . We have observed a similar result in T47D cells , suggesting that BTC generally activates ErbB3 to a higher degree than EGF. NDF induced the strongest increase in ErbB3 phosphotyrosine, particularly considering that less ErbB3 was immunoprecipitated from the NDF treated extracts (reprobing ± Figure 3 lower panel). The NDF-and BTC-induced increase in ErbB3 tyrosine phosphorylation correlates with their differential eects on the cell cycle, suggesting that BTC and NDF cause an increase in S phase fraction because of their ability to activate ErbB3.
Intracellular signalling pathways involved in NDF-induced cell cycle progression
To identify intracellular signal transduction pathways linked to NDF-induced cell cycle changes, we treated SKBR3 cells with speci®c kinase inhibitors. Using FACS analyses we have observed that the earliest detectable eect of NDF on the cell cycle pro®le of SKBR3 cells is seen at 15 h as a shift from G1 to S phase (not shown). By 20 h, most of these S phase cells have progressed to G2 and hence the ligand eect is seen more clearly. Accordingly, the analyses were performed on cells after 20 h of NDF treatment in the presence or absence of speci®c kinase inhibitors. Figure 2 Phosphopeptide mapping of EGF-, BTC-and NDFactivated ErbB2. SKBR3 cells were deprived of phosphate and serum for 12 h prior to labelling with 32 P-orthophosphate for 4 h. Cells were left untreated (control) or stimulated with 1 nM EGF, BTC or NDF for 10 min. Immunoprecipitated ErbB2 was subjected to tryptic phosphopeptide analysis as described in Materials and methods. 1000 c.p.m. was spotted onto TLC plates and separated by ascending chromatography in the ®rst dimension and electrophoresis at pH 1.9 in the second dimension. Ligand induced peptides appear similar in all cases and are labelled on the top right map (EGF) Figure 3 Tyrosine phosphorylation of ErbB3 in response to NDF and BTC but not EGF. SKBR3 cells were treated with 1 nM of the indicated ligands for 10 min and lysed. ErbB3 was immunoprecipitated from 1 mg total lysate using C17 antiserum, subjected to SDS ± PAGE, blotted and probed with an antiphosphotyrosine mAb. The membrane was then stripped and reprobed with ErbB3 speci®c C17 serum Treatment of SKBR3 cells with 4 mM PD153035, an inhibitor of ErbB1 and ErbB2 (Arteaga et al., 1997) , blocked both the basal and NDF-induced phosphorylation of ErbB2 and ErbB3 (not shown), showing that ErbB2 kinase is required for activation of ErbB3, both in the presence and absence of NDF. This inhibitor caused a G1 block in the absence of ligand and prevented NDF-induced G1 progression (Figure 4 ). The eects of PD153035 are likely mediated via blockage of ErbB2 kinase since CGP59326B, a specific inhibitor of ErbB1 but not ErbB2 (Traxler et al., 1996) had no eect on the cell cycle pro®le of SKBR3 (our unpublished data).
It is well established that activated ErbB receptors stimulate MAPK pathways. ERKs have been associated with growth (Pages et al., 1993) , whereas the stress activated p38 MAPKs have been associated with apoptosis and survival (Xia et al., 1995; Schwenger et al., 1997; Zechner et al., 1998 ). An inhibitor of MEK 1 and 2 (PD98059) which blocks ERK1/ERK2 activation (Alessi et al., 1995) , and inhibitors of p38 MAPKs (SB203580) (Figure 4 ) and (SB202190, not shown) did not aect the cell cycle pro®le of SKBR3 cells in the absence of ligand and did not prevent NDF-induced cell cycle progression, suggesting that these kinases are not essential for basal or NDF-induced DNA synthesis. SB203580 and SB202190 were used at 4 mM, a concentration which is speci®c for p38a and p38b/b2 MAPK and does not aect JNK (Whitmarsh et al., 1997) .
The cytoplasmic tyrosine kinase c-Src lies downstream of ErbB receptors and can be found associated with ErbB1 and ErbB2 (Luttrell et al., 1994; Muthuswamy et al., 1994) . The c-Src inhibitor CGP77675 caused a slight accumulation in G1 in the absence of NDF (70% in control vs 76% in inhibitor treated cells) but had no eect on NDF-induced cell cycle progression. In contrast, inhibitors of PI3K (LY294002) (Vlahos et al., 1994) , and FRAP (rapamycin), an upstream regulator of S6 kinase which lies on the PI3K pathway (Pullen and Thomas, 1997) , caused a G1 block in the presence or absence of ligand ( Figure 4 ).
The data obtained with these inhibitors suggest that in SKBR3 cells, G1 progression is dependent on ErbB2/ErbB3 and the PI3K pathway. In comparison to the other ErbB receptors, the cytoplasmic tail of ErbB3 contains more potential docking sites for the p85 subunit of PI3K (Fedi et al., 1994; Prigent and Gullick, 1994) , allowing it to couple eciently to this kinase . Furthermore, ErbB3 is tyrosine phosphorylated in untreated SKBR3 cells and ligand-induced increases in its phosphorylation correlate with G1 progression. Therefore, it seems possible that both basal and ligand-induced DNA synthesis proceed via ErbB2 transactivation of ErbB3 and subsequent stimulation of the PI3K pathway. In contrast, neither ERK1/2 nor p38 MAPK are required for basal or NDF-induced G1 progression.
Comparison of NDF and BTC-induced signalling pathways
We next examined the eects of NDF and BTC on long-term activation of intracellular signalling pathways. Any dierences observed might explain why NDF and BTC both induce G1 progression whereas only NDF induces apoptosis. Firstly, we examined the eect of NDF and BTC on the activity of ERK1/ ERK2, and p38 MAPKs using antisera speci®c for the dually phosphorylated, active forms of these kinases. The time course and extent of activation of ERK1/ ERK2 was similar following NDF or BTC treatment of SKBR3 cells, with maximal activity reached between 1 and 10 min (Figure 5a ). ERK activity dropped at 90 min and returned to basal level by 1 day. The phospho-p38 antiserum recognizes p38a and p38b/b2 MAPK isoforms, henceforth referred to as p38 MAPKs. EGF (not shown) as well as NDF and BTC (Figure 5b ) all activated p38 MAPK at 10 min. The initial activation was slightly more prolonged with NDF than with BTC. However, of particular interest was the second phase of p38 MAPK activation, seen 2 ± 3 days after treatment with NDF but not BTC. This second phase of NDF-induced p38 MAPK activation was less pronounced than the ®rst, but was reproduced Figure 4 Eect of kinase inhibitors on NDF induced G1 progression. SKBR3 cells were plated at 1.5610 5 cells per 10 cm dish and left overnight to attach. Inhibitors of p38 MAPK (4 mM SB203580), MEK1 and 2 (20 mM PD98059), ErbB (4 mM PD153035), PI3K (50 mM LY294002), S6K (20 nM rapamycin) or c-Src (2 mM CGP77675) were added either 90 min before treatment with 1 nM NDF or to otherwise untreated cultures, as indicated. Cells were harvested by trypsinization 20 h later, stained with PI and analysed for cell cycle pro®le by FACS analysis in several independent experiments and coincides with the onset of apoptosis.
Ligand-induced stimulation of c-Src was also tested in a c-Src autophosphorylation assay. Activation of cSrc was seen at 10 min with both NDF and BTC. However, NDF induced a second peak of c-Src activity at 2 days, a time when BTC had little or no eect (Figure 6a ). ErbB2/c-Src complexes were also measured following immunoprecipitation of c-Src from NDF treated cells. c-Src was associated with ErbB2 even in unstimulated cells (Figure 6b) . Furthermore, the level of association increased with NDF treatment, reaching a maximum at 30 min. Although the precise role of cSrc in ErbB receptor signalling is not certain, it has been shown to phosphorylate ErbB receptors on speci®c tyrosine residues which could serve as c-Src binding sites (Stover et al., 1995) . This possibility agrees well with our observation that in the presence of NDF, the level of the c-Src/ErbB2 complex is still high at 30 min, a time when c-Src activity had started to decline. However, at 2 days, a time when c-Src activity is also high, the level of the ErbB2/c-Src complex was low. This is at least partially due to down-regulation of ErbB2 levels , but may suggest that activation of c-Src at this time is due to a dierent upstream event.
The importance of the PI3K pathway for the growth of SKBR3 cells was shown with the inhibitors Figure 5 Comparison of signal transduction by NDF and BTC. SKBR3 cells were treated with 1 nM of NDF or BTC for the indicated times or left untreated (con). (a, b) 70 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active forms of ERK 1 and 2 (a). The blot was stripped and then probed for the active forms p38 MAPK (b). (c) ErbB3 was immunoprecipitated from 1 mg total lysate, subjected to SDS ± PAGE, blotted and probed with antiserum speci®c for the p85 subunit of PI3K. (d) 50 mg total lysate was subjected to SDS ± PAGE, blotted and probed with antisera speci®c for the active form of PKB LY294002 and rapamycin (Figure 4) . It seemed likely that the same pathway would also be important for NDF-induced cell cycle progression since NDF strongly activates ErbB3. We tested directly for activation of the PI3K pathway. Firstly, we measured coimmunoprecipitation of ErbB3 and p85 after activation by NDF and BTC. NDF treatment of SKBR3 cells increased p85 binding to ErbB3 for at least 1 day (Figure 5c ). BTC also increased p85-ErbB3 association but to a lesser extent than NDF and for a shorter period of time (Figure 5c ). EGF, which had little eect on ErbB3 phosphorylation (Figure 3) did not cause an increase in p85-ErbB3 complexes (data not shown). Secondly, we measured the activity of protein kinase-B (PKB) which lies downstream of PI3K (Franke et al., 1995; Vanhaesebroeck et al., 1997) , using an activation-speci®c (Ser473) antiserum. Following 10 min treatment, NDF and BTC activated PKB to similar extents. However, after 12 h the BTCinduced activity returned to basal whereas NDFinduced PKB remained active for at least 1 day (Figure 5d ). This corresponds well with the level of ErbB3/p85 complex ( Figure 5c ).
In summary, our analysis of ligand-induced signal transduction, combined with the use of speci®c kinase inhibitors, suggest that NDF and BTC initially induce cell cycle progression via ErbB2 mediated transactivation of ErbB3 and subsequent stimulation of the PI3K pathway. Apoptosis, which is seen after 2 ± 3 days treatment with NDF but not BTC, correlates with the second phase of c-Src and p38 MAPK activation.
NDF induces growth inhibition via ErbB2/ErbB3 dimers
Growth inhibition by NDF appears to be speci®c for ErbB2 overexpressing breast tumour cells. However, the in¯uence that the other ErbB receptors have on the eects of NDF has not been examined. To address this question, we used retroviral vectors to generate three dierent pools of SKBR3 cells; those ectopically expressing ErbB4 (SKBR3-ErbB4), and those expressing enhanced levels of ErbB1 (SKBR3-ErbB1) or ErbB3 (SKBR3-ErbB3). Expression was con®rmed by FACS and Western analyses. Figure 7 shows that NDF-induced growth inhibition, as measured in a colony assay, is not aected by increased ErbB1 expression. However, increased ErbB3 expression markedly enhanced growth inhibition by NDF, con®rming the importance of this receptor. Expression of ErbB4 also enhanced NDF-induced growth inhibition but to a lesser extent. The increased growth inhibition in the presence of ErbB4 may indicate an additive eect of NDF induced ErbB2/ErbB4 dimers or increased phosphorylation of ErbB3 in the presence of ErbB4. Western blot analysis of lysates from SKBR3-ErbB4 cells revealed that both ErbB3 and ErbB4 were activated in response to NDF. However, NDF-induced phosphorylation on ErbB3 was far stronger than on ErbB4 (not shown). Apparently NDF activates predominantly ErbB2/ErbB3 dimers in these cells even when ErbB4 is present. BTC was more ecient than NDF at phosphorylating ErbB4. However, SKBR3-ErbB4 was not growth inhibited by BTC. Instead, the presence of ErbB4 appeared to increase the growth eect of BTC (Figure 7) . Interestingly, the growth of SKBR3-ErbB1 was inhibited by BTC (61.7% of controls; Figure 7) and EGF (34.3% of controls; not shown). Similar results have been reported with other ErbB1 overexpressing tumour cell lines (Bromberg et al., 1998) . In summary, NDFinduced growth inhibition appears to be mediated by ErbB2/ErbB3 dimers. Any additive eect of NDFinduced ErbB2/ErbB4 dimers would be limited by the apparent preference of NDF for ErbB3 and would exclude BTC-induced ErbB2/ErbB4 dimers.
NDF-induced apoptosis requires p38 MAPK activity
NDF-induced apoptosis in SKBR3 cells can be detected by propidium iodide (PI) staining and FACS analysis following 3 days of ligand treatment . Apoptotic cells are detected as G2 (tetraploid) cells with decreased forward light scatter (FSC). We tested the kinase inhibitors for their ability to inhibit NDF-induced apoptosis. Representative FACS analyses are shown in Figure 8 . Per cent apoptosis was calculated from the indicated gated area and the important results are listed in Table 2 . In the absence of inhibitor, cells treated for 3 days with NDF showed 8.0 ± 11.3% apoptosis compared to 1.6 ± 2.3% in controls. In the presence of the MEK1/MEK2 inhibitor, or the c-Src inhibitor, the extent of NDFinduced apoptosis did not change, indicating that neither c-Src nor the ERK pathway is required. In the presence of the p38 MAPK inhibitors SB203580 ( Figure 8 , Table 2 ) or SB202190 (not shown), however, NDF-induced apoptosis was markedly reduced (3.1% as compared to 9.7% with NDF alone), suggesting that p38 MAPK is required for NDF-induced apoptosis.
Treatment of cells with PD153035, LY294002 and rapamycin also prevented NDF-induced apoptosis from G2/M. However, these compounds all caused a G1 delay (Figures 4, 8) and their apparent ability to protect from NDF-induced apoptosis may merely re¯ect the inability of the cells to enter G2/M.
A second phase of p38 MAPK activity is required for apoptosis: role of c-Src
Since NDF activated p38 MAPK at 10 min and again at 2 ± 3 days (Figure 5c ), each phase of activation was independently inhibited and apoptosis was measured in the following experiment. SKBR3 cells were exposed to SB203580 before and during a 5 h NDF treatment or for 3 days subsequent to the NDF treatment. We have previously shown that short exposures (45 min) to NDF are sucient to induce apoptosis 2 ± 3 days later . Table 2 shows that SB203580 protects from NDF-induced apoptosis only when present during the second phase of p38 MAPK activity. The initial activation of p38 MAPK is apparently neither sucient nor required for NDFinduced apoptosis. This correlates well with our observation that BTC, which does not induce apoptosis, only stimulates the ®rst phase of p38 MAPK activation (Figure 5c ).
NDF also induced two peaks of c-Src activity, which prompted us to test whether c-Src is upstream of p38 MAPK. SKBR3 cells were pretreated for 90 min with CGP77675 or PP1, two non-related c-Src kinase inhibitors, then treated with NDF for 10 min. Western blot analysis revealed that both inhibitors blocked the early activation of p38 MAPK by NDF (Figure 9a ) as well as by BTC or EGF (not shown). The ErbB inhibitor PD153035 also blocked NDF-induced p38 MAPK activation, whereas LY294002 and rapamycin had no eect (our unpublished data). We have previously shown that NDF-induced apoptosis is strongest in low density cultures . Therefore, we performed immunostaining with the activation-speci®c p38 MAPK antiserum to allow the use of low density cultures. The results show that active p38 MAPK is nuclear and, as seen in the Western analysis, CGP77675 essentially blocks short term NDF induction of p38 MAPK activity ( Figure  9b ). In contrast, the activity of p38 MAPK at 2 days was only partially blocked by the c-Src inhibitor (Figure 9c ) suggesting that another upstream molecule also contributes to its activity. These results provide an explanation for the observation that CGP77675 did not protect from NDF-induced apoptosis (Table 2) . In summary, all three ligands induced short-term activation of p38 MAPK in a c-Src-dependent manner. Figure 8 Detection of NDF-induced apoptosis in the presence of speci®c kinase inhibitors. SKBR3 cells were left untreated (control) or were treated as described in Figure 4 except that they were harvested after a 3-day exposure to NDF. Following FACS analysis, data were plotted as DNA content (PI staining, x axis) versus cell size (FSC, y axis). Apoptotic cells were detected as G2 cells with decreased FSC as described previously . Percentage apoptosis was calculated by applying an identical but arbitrary gate to each sample (boxed region) Percentage apoptosis was measured in the presence and absence of NDF and speci®c kinase inhibitors as described in Figure 8 . In some cases, exposure to NDF was reduced to 5 h and inhibitor added 90 min before and during, or immediately after the 5 h treatment However, only NDF caused a second, c-Src-independent increase in p38 MAPK activity, which was required for apoptosis.
Discussion
ErbB2 is overexpressed in a variety of human cancers including breast and ovarian (Berger et al., 1988; Slamon et al., 1989 ). ErbB2 appears to contribute to the malignancy and patients whose tumours display elevated ErbB2 have a worse prognosis (Hynes and Stern, 1994) . In addition, the high level of receptor expression in the tumour relative to normal tissues, make ErbB2 an excellent target for speci®c cytotoxic reagents. ErbB2 has a high level of phosphotyrosine in many tumour cells where it is overexpressed (Alimandi et al., 1995; DiGiovanna et al., 1995) , suggesting that the receptor continuously activates signalling pathways required for tumour cell growth. In this paper, we show that inhibition of ErbB2 kinase leads to G1 arrest in SKBR3 cells, indicating that ErbB2 is required for G1 progression. Since LY294002 and rapamycin also induced a G1 arrest, it is possible that ErbB2 promotes cell cycle progression in these cells via activation of the PI3K/S6 kinase pathway. This would most likely be mediated by ErbB3, since it contains more PI3K docking sites than other ErbB receptors and in SKBR3 cells, is kept partially active by ErbB2 kinase (Figure 3 and text) . Furthermore, we observed a correlation between ligand-induced cell cycle progression and ErbB3 association with PI3K, suggesting that activation of this pathway induces G1 progression. These data raise the interesting possibility that the growth of ErbB2 overexpressing breast tumour cells which co-express ErbB3 is dependent on heterodimers of ErbB2/ErbB3. NDF has been shown to inhibit the growth of various tumour cells Peles et al., 1992; Daly et al., 1997; Grasso et al., 1997) . In a previous publication, we showed that NDF induced growth inhibition is speci®c to ErbB2 overexpressing breast tumour cells and in SKBR3 cells, is mediated through apoptosis. This was accompanied by downregulation of ErbB2 protein levels and activity . However, at that time, it was not certain whether downregulation of ErbB2 had a causative role in the apoptosis. The results presented here show that inhibition of ErbB2 leads to a G1 arrest in the absence of apoptosis. Thus, it appears that the loss of ErbB2 signalling per se is not sucient to cause apoptosis. This is consistent with other studies showing that single-chain antibody mediated down-regulation of ErbB2 also leads to growth inhibition (Jannot et al., 1996) but not to apoptosis in SKBR3 cells (R Neve, manuscript in preparation).
In contrast to the growth inhibitory eect of NDF on ErbB2 overexpressing tumour cells, this ligand stimulates the in vivo growth of mammary epithelium (Jones et al., 1996) and the in vitro growth of normal mammary cells and breast tumour cell lines with low levels of ErbB2 (Marte et al., 1995; Graus-Porta et al., 1995; Beerli and Hynes, 1996; Lewis et al., 1996) . In this paper, we show that NDF initially induces DNA synthesis, even in SKBR3 cells which are growth inhibited by NDF. The growth inhibitory eect of Figure 9 Eect of c-Src kinase inhibitors on p38 MAPK activation. (a) SKBR3 cells were pretreated for 90 min with cSrc inhibitors (10 mM PP1 or 2 mM CGP77675) or normal media and then stimulated with NDF for 10 min as indicated. Following lysis, 50 mg total protein was subjected to SDS ± PAGE, blotted and probed with anti-phospho-speci®c p38 antiserum. (b, c) Immunocytochemical detection of active p38 MAPK after 10 min (b) or 2 days (c) NDF treatment. The cSrc inhibitor, CGP77675 was added at 2 mM 1 day prior to ®xation NDF occurs subsequent to G1 progression and involves a delay in G2 and apoptosis from G2/M. Like NDF, BTC also induced G1 progression but to a lesser extent. In contrast, EGF had no eect on the growth or cell cycle pro®le of SKBR3 cells. We examined the signalling pathways involved in ErbB ligand-induced DNA synthesis using speci®c kinase inhibitors and by comparison of the signalling events induced by NDF, BTC and EGF. The MAPK pathway has been linked to cell growth in other systems (Pages et al., 1993) . However, inhibition of ERK1 and ERK2 by treatment of the cells with the MEK inhibitor (data not shown), had no eect on basal or ligand-induced cell cycle progression, indicating that this pathway is not involved in G1 progression in SKBR3 cells. Furthermore, all three ligands activated ERK1/ERK2 to a similar extent, despite their dierent growth eects. Instead, the major dierence between the three ErbB ligands tested, was their ability to activate ErbB3 and subsequently, the PI3K pathway. NDF and BTC, but not EGF promoted an increase in the tyrosine phosphorylation of ErbB3 and the level of its association with PI3K. NDF, which is a direct ligand for ErbB3, had the strongest eect over the longest time period, correlating with its strong induction of G1 progression. EGF, which is not mitogenic in SKBR3 cells, neither increased the level of ErbB3 tyrosine phosphorylation, nor induced ErbB3/p85 complex formation. EGF and BTC do not bind ErbB3 directly but can, to dierent extents, activate ErbB3 via lateral transmission of the signal through ErbB2 (Beerli and Graus-Porta et al., 1997) . In T47D cells (Beerli and and in SKBR3 cells (this paper) we have observed that BTC is more pro®cient than EGF at transactivating ErbB3. The process by which signals are transmitted from ErbB1 via ErbB2 to ErbB3 is not completely described but could be via formation of larger complexes or breaking up the active dimer complex followed by re-dimerization (Lax et al., 1991; Murali et al., 1996; Gamett et al., 1997) . We propose that activation of ErbB2/ErbB3 heterodimers and subsequent coupling to the PI3K pathway is important for NDF-and BTC-induced cell cycle progression. The G1 delay caused by inhibitors of this pathway demonstrates its general importance for cell cycle progression in SKBR3 cells.
A consensus is emerging that the NDF-activated ErbB2/ErbB3 heterodimer is the most potent ErbB signalling complex, in terms of growth and transformation (Alimandi et al., 1995; Wallasch et al., 1995; Pinkas-Kramarski et al., 1996) . In addition to the role of this dimer in cell cycle progression, we also show that the activated ErbB2/ErbB3 heterodimer has a major role in NDF-induced apoptosis. However, the downstream signalling molecules, which mediate these two eects, appear to dier. Our data show that NDF mediates apoptosis via activation of p38 MAPK. Short-term activation of p38 MAPK (10 min) was common to all ErbB ligands tested but was neither sucient nor necessary for apoptosis. Only NDF induced a second phase of p38 MAPK activity (2 ± 3 days), and only this latter phase was required for NDF-induced apoptosis. Apoptosis was seen from day 2 onwards but was blocked by a p38 MAPK inhibitor, which had no eect on G1 to S phase progression. It is possible that the stronger and more prolonged activation of ErbB3 by NDF leads, indirectly, to apoptosis. Alternatively, NDF may activate distinct pathway(s) which is (are) responsible for apoptosis. It should also be mentioned that BTC, but not NDF, activates ErbB1, which may relieve the cells from the signals inducing apoptosis. However, addition of EGF together with NDF does not protect from apoptosis .
The small GTP-binding proteins Rac1 and Cdc42, which are stimulated by many extracellular ligands (Hall, 1998) , lie upstream of p38 MAPKs (Coso et al., 1995; Minden et al., 1995) . Rac1 and Cdc42 are activated by PI3K (Hall 1998) and by Src family members (Hauck et al., 1998) . Our results show that in SKBR3 cells, c-Src lies upstream of p38 MAPK. Firstly, both c-Src and p38 MAPK were activated in response to ErbB ligands. Secondly, the short-term activation of p38 MAPK by these ligands, was blocked almost completely by two non-related c-Src inhibitors, but not by LY294002, an inhibitor of PI3K. It should be noted that the c-Src inhibitors used in this study, also block other Src family members (Hanke et al., 1996) , which may contribute to p38 MAPK activation. The activity of p38 MAPK at 2 days, however, was only partially blocked by a c-Src inhibitor, suggesting that another upstream molecule also contributes to its activity at this time.
The role of p38 MAPK in apoptosis has been extensively investigated but still remains unclear. In some cells, induction of p38 MAPK leads to apoptosis (Xia et al., 1995; Schwenger et al., 1997) , whereas in others its activation protects from apoptosis (Zechner et al., 1998) . Some of this variability may arise from the fact that dierent isoforms of p38 MAPK have dierent functions (Wang et al., 1998) . It seems likely that either p38a and/or p38b/b2 are responsible for NDF-induced apoptosis in SKBR3 cells since only these isoforms are inhibited by SB203580 (Wang et al., 1997; Enslen et al., 1998) . In PC12 cells, survival and death are controlled by the opposing action of the ERK and p38 MAPK pathways (Xia et al., 1995) . However, in SKBR3 cells, ERK1 and ERK2 were activated by all three ErbB ligands and their inhibition did not aect cell cycle progression or apoptosis.
At this time, we can only speculate as to why NDF treated cultures show a second wave of p38 MAPK activity and the role of p38 MAPK in apoptosis. However, it is important to note that inhibition of p38 MAPK not only blocked apoptosis but allowed the cells to continue cycling. This was evident from the percentage of cells in G2/M at 3 days (control=21, NDF=34, NDF+SB203580=25) and also from a colony formation assay (not shown) which demonstrated that NDF-induced growth inhibition is blocked in the presence of SB203580.
It is possible that p38 MAPK is activated after 2 ± 3 days NDF treatment as a consequence of stress induced by a prolonged G2 block. In NDF treated cultures, the level of Cdk1 Tyr15 phosphorylation remained high from day 1 onwards, suggesting that the cells were paused at a G2 checkpoint. Cdc25C, the phosphatase responsible for activating Cdk1 at the G2/M transition, has an important role in the checkpoint controlling entry into mitosis (Nurse, 1997) . It is possible, therefore, that NDF may aect the activity of Cdc25C or perhaps other upstream modulators of Cdk1 activity. However, the observation that percentage G2 is decreased at 2 days compared to 1 day suggests that the majority of the NDF-treated cells undergo at least one round of mitosis. BTC, a mitogen for SKBR3 cells, also increased the percentage of cells in G2/M, but only at 1 day. Apparently, BTC-treated cultures continue cycling, whereas NDF treated cells eventually undergo apoptosis.
Since NDF strongly induced G1 progression, we speculate that NDF treated SKBR3 cells progress too rapidly through G1/S and attempt to stop in G2 due to abnormal S phase progression. Comprised checkpoint control is a characteristic of tumour/immortalized cells (Lane and Nigg, 1996) and premature release from a G2 checkpoint may explain the second phase of p38 MAPK activation we observed. Recently, p38 MAPK activation was shown to be essential for nocodazoleinduced M phase block (Takenake et al., 1998) , suggesting a role in the mitotic spindle assembly checkpoint. In SKBR3 cells, NDF-induced apoptosis may, therefore, be a direct consequence of inappropriate mitotic entry, leading to apoptosis from a p38 MAPK-dependent spindle checkpoint. Further experiments are now being performed to address this possibility.
In conclusion, the results suggest that overexpressed ErbB2 stimulates G1 progression via ErbB2 transactivation of ErbB3 and stimulation of the PI3K/S6 kinase pathway. NDF and BTC induce G1 progression via the same pathway but NDF also induces apoptosis from G2/M via p38 MAPK. Further analysis of these pathways may reveal therapeutic targets for the growth inhibition of tumours dependent on ErbB2 or on ErbB ligands. The possibility of using NDF to trigger apoptosis in ErbB2 overexpressing tumours also warrants further investigation.
Materials and methods
Materials
Recombinant human ErbB ligands included NDF (Neomarkers, Fremont, CA, USA), EGF (Sigma) and BTC (R & D Systems). Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989) , ErbB3 speci®c anity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2 MAPK (Thr180/ Tyr182) polyclonal antiserum, anti-phospho-speci®c p44/42 ERK (Thr202/Tyr204) polyclonal antiserum, anti-phosphospeci®c Akt/PKB (Ser473) polyclonal antiserum, antiphospho-speci®c Cdc2 (Cdk1) (Tyr15) polyclonal antiserum (New England Biolabs MA, USA), anti-Cdc2 polyclonal antiserum (Gibco), anti-cyclin A polyclonal antiserum (Lisztwan et al., 1998, supplied by W Krek, FMI) , and anti cyclin B1 polyclonal antiserum, H-433 (Santa Cruz).
Speci®c kinase inhibitors were stored as 1000 ± 5000 times concentrated stock solutions in DMSO and usually added 90 min prior to ligand treatment. These included: PD153035 (4 mM), an ErbB speci®c tyrosine kinase inhibitor (Ward et al., 1994; Fry et al., 1995) ; LY294002 (Calbiochem), a reversible inhibitor of PI3K (Vlahos et al., 1994) used at 10 ± 50 mM; the c-Src family kinase inhibitors PP1(Calbiochem) (Hanke et al., 1996) and CGP77675 (Dr J Green, Novartis) (Missbach et al., 1999) used at 10 mM and 2 mM, respectively; SB203580 and SB202190 (Calbiochem), inhibitors of p38a and p38b/b2 MAPKs used at 4 mM; PD98059 (New England Biolabs MA, USA), an inhibitor of MEK1 and 2 used at 20 mM; rapamycin (Sandoz) an inhibitor of FRAP/TOR was used at 20 nM.
Cell culture
SKBR3 human breast tumour cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% foetal calf serum. Human ErbB1, ErbB3 and ErbB4 were introduced into SKBR3 cells using pBabe based retroviruses . Pools of cells expressing ErbB1 were selected with 450 mg/ml hygromycin, those expressing ErbB3 or ErbB4 were selected with 2 mg/ml puromycin. Expression was con®rmed by FACS and Western analyses. Anchorage dependent colony assays were performed as described previously .
BrdU labelling
Low density cultures of SKBR3 cells were treated with 10 mM BrdU (Amersham Corp., Arlington Heights, IL, USA) for 3 h and then harvested by trypsinization immediately (to measure DNA synthesis) or 9 h after removal of BrdU (to follow cell cycle progression). Cells were rinsed and resuspended in 200 ml PBS and then ®xed by addition of 800 ml ethanol. Following at least 30 min in ethanol, cells were spun and resuspended sequentially in 2 M HCl/0.5% Tween 20 for 20 min at room temperature, 0.1 M Na 2 B 4 O 7 10 H 2 O (pH 8.5) brie¯y and then 200 ml PBS/0.5% Tween 20/ 1% BSA. 5 ml of FITC conjugated anti-BrdU antibody (Becton Dickinson) was added and the cells incubated at RT for 30 min before being washed once in PBS/0.5% Tween 20/ 1% BSA and then resuspended in 500 ml PBS/5 mg/ml PI. Samples were analysed by FACS analysis and plotted as FITC (BrdU) versus DNA content (PI).
FACS Analysis
Cells were plated at a density of 1.0610 5 cells per 10 cm dish and left overnight to attach before treatment with 1 nM NDF, BTC or EGF. Prior to FACS analysis, cells were harvested by trypsinization, rinsed in PBS and incubated for 20 ± 90 min in PBS containing 5 mg/ml propidium iodide (PI), 100 mg/ml RNAse A, 5 mM EDTA, 5 mM EGTA and 0.1% NP40. DNA content (PI¯uorescence) was expressed in cell cycle histograms and plotted against forward light scatter (FSC) to measure apoptosis as described previously . Apoptotic cells were identi®ed as G2 (tetraploid) cells with decreased FSC. Identical gating was used to calculate percentage apoptosis in all samples within a single experiment.
Immunoprecipitation and Western blots
For analysis of ErbB receptors and associated proteins, cells were solubilized in Triton extraction buer (50 mM Tris, pH 7.5, 5 mM EGTA, 150 mM NaCl, 1% Triton X-100, 2 mM sodium orthovanadate, 50 mM sodium¯uoride, 10 mg/ ml leupeptin, 10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl uoride (PMSF)) for 10 min on ice. The lysates were clari®ed by centrifugation at 16 000 g for 10 min. For immunoprecipitations, equal amounts of protein were incubated with speci®c antibodies for 1 h on ice. Immune complexes were collected with protein A-or protein G-sepharose (Sigma) and washed three times with extraction buer and once with TNE buer (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA).
Total lysates or immunoprecipitated proteins were boiled in sample buer, subjected to SDS ± PAGE and blotted onto polyvinylidene di¯uoride membranes. After blocking with 20% horse serum (Gibco BRL) in TBS (50 mM Tris, pH 7.5, 150 mM NaCl) containing 0.05% Tween-20, membranes were probed with speci®c antibodies. Proteins were visualized with peroxidase-coupled secondary antibody using the ECL detection system (Amersham). Stripping of membranes was performed in SDS buer (62.5 mM Tris, pH 6.8, 2% SDS, 100 mM b-mercaptoethanol) for 30 min at 658C, membranes were then washed in TBS/0.05% Tween-20 and reprobed with the indicated antibodies.
c-Src kinase assay SKBR3 cells were lysed in extraction buer (50 mM Tris, pH 7.5, 120 mM NaCl, 1% Triton, 5 mM EDTA, 1 mM EGTA, 50 mM sodium¯uoride, 20 mM b-glycerophosphate, 15 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 0.5 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). After preclearing of lysates with protein G-Sepharose (Sigma), c-Src was immunoprecipitated with mAb 327 (Calbiochem) and protein G Sepharose. Immunoprecipitates were washed twice with extraction buer and twice with kinase buer (20 mM Tris, pH 7.5, 5 mM MgCl 2 ). The immune complexes were incubated for 10 min at 308C in 30 ml kinase buer containing 5 mM ATP and 5 mCi [g 32 P]-ATP. The reaction was stopped with SDS sample buer, proteins were subjected to SDS ± PAGE (10% gel) and blotted onto PVDF membranes. The membrane was analysed using a PhosphorImager (Molecular Dynamics) and the signal was normalized for the amount of immunoprecipitated c-Src which was quanti®ed by immunoblotting and ImageQuant Software.
Immunocytochemical detection of`active' p38 MAPK SKBR3 cells were plated at low density on chamber slides and left overnight to attach. CGP77675 was added at 2 mM 24 h prior to ®xation in 4% paraformaldehyde and 1 nM NDF added 10 min or 2 days before ®xation. Slides were blocked in 10% goat serum for 90 min and incubated overnight in 1 : 100 anti-phospho-p38 MAPK serum in TBS containing 0.1% Triton X-100 and 5% goat serum. Washes were performed in TBS containing 0.1% Triton and speci®c binding was visualized with DAB using the ABC Elite Kit (Vector Labs, CA, USA) as speci®ed by the manufacturer.
Phosphopeptide mapping
Cells were deprived of phosphate and serum for 12 h prior to labelling with 32 P orthophosphate (Amersham) for 4 h. After stimulation for 10 min with growth factors, ErbB2 was immunoprecipitated using 21N antiserum. The proteins were resolved by SDS ± PAGE. ErbB2 was excised from the gel and tryptic phosphopeptide mapping performed exactly as described (Olayioye et al., 1998) 
